Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Endothelial PAS domain-containing protein 1 (EPAS1) gene polymorphisms and response to anti-VEGF therapy in the comparison of AMD treatments trials (CATT).

Literature DB >> 24813631

Endothelial PAS domain-containing protein 1 (EPAS1) gene polymorphisms and response to anti-VEGF therapy in the comparison of AMD treatments trials (CATT).

Stephanie A Hagstrom¹, Gui-Shuang Ying², Gayle J T Pauer³, Jiayan Huang², Maureen G Maguire², Daniel F Martin¹.

Abstract

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2014 PMID： 24813631 PMCID： PMC4122574 DOI： 10.1016/j.ophtha.2014.02.025

Source DB: PubMed Journal: Ophthalmology ISSN： 0161-6420 Impact factor: 12.079

× No keyword cloud information.

4 in total

1. Retinal disease in mice lacking hypoxia-inducible transcription factor-2alpha.

Authors: Kan Ding; Marzia Scortegagna; Robyn Seaman; David G Birch; Joseph A Garcia
Journal: Invest Ophthalmol Vis Sci Date: 2005-03 Impact factor: 4.799

2. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.

Authors: Andrew J Lotery; Jane Gibson; Angela J Cree; Susan M Downes; Simon P Harding; Chris A Rogers; Barnaby C Reeves; Sarah Ennis; Usha Chakravarthy
Journal: Ophthalmology Date: 2013-09-23 Impact factor: 12.079

3. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells.

Authors: H Tian; S L McKnight; D W Russell
Journal: Genes Dev Date: 1997-01-01 Impact factor: 11.361

4. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).

Authors: Stephanie A Hagstrom; Gui-Shuang Ying; Gayle J T Pauer; Gwen M Sturgill-Short; Jiayan Huang; David G Callanan; Ivana K Kim; Michael L Klein; Maureen G Maguire; Daniel F Martin
Journal: Ophthalmology Date: 2013-01-18 Impact factor: 12.079

4 in total

8 in total

1. Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.

Authors: Laura Lorés-Motta; Moeen Riaz; Michelle Grunin; Jordi Corominas; Freekje van Asten; Marc Pauper; Mathieu Leenders; Andrea J Richardson; Philipp Muether; Angela J Cree; Helen L Griffiths; Connie Pham; Marie-Claude Belanger; Magda A Meester-Smoor; Manir Ali; Iris M Heid; Lars G Fritsche; Usha Chakravarthy; Richard Gale; Martin McKibbin; Chris F Inglehearn; Reinier O Schlingemann; Amer Omar; John Chen; Robert K Koenekoop; Sascha Fauser; Robyn H Guymer; Carel B Hoyng; Eiko K de Jong; Andrew J Lotery; Paul Mitchell; Anneke I den Hollander; Paul N Baird; Itay Chowers
Journal: JAMA Ophthalmol Date: 2018-08-01 Impact factor: 7.389

Review 2. Genetics and genetic testing for age-related macular degeneration.

Authors: A Warwick; A Lotery
Journal: Eye (Lond) Date: 2017-11-10 Impact factor: 3.775

3. The relationship between autophagy-related genes and the staging and prognosis of thyroid cancer: a bioinformatics analysis.

Authors: Qin Xu; Shan Gao; Jidong Miao
Journal: Gland Surg Date: 2021-08

4. A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular age-related macular degeneration.

Authors: Laura Lorés-Motta; Freekje van Asten; Philipp S Muether; Dzenita Smailhodzic; Joannes M Groenewoud; Amer Omar; John Chen; Robert K Koenekoop; Sascha Fauser; Carel B Hoyng; Anneke I den Hollander; Eiko K de Jong
Journal: Pharmacogenet Genomics Date: 2016-01 Impact factor: 2.089

Endothelial PAS domain-containing protein 1 (EPAS1) gene polymorphisms and response to anti-VEGF therapy in the comparison of AMD treatments trials (CATT).

1. Retinal disease in mice lacking hypoxia-inducible transcription factor-2alpha.

2. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.

3. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells.

4. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).

1. Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.

Review 2. Genetics and genetic testing for age-related macular degeneration.

3. The relationship between autophagy-related genes and the staging and prognosis of thyroid cancer: a bioinformatics analysis.

4. A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular age-related macular degeneration.

Review 5. Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration.

6. Anti-VEGF Drugs Influence Epigenetic Regulation and AMD-Specific Molecular Markers in ARPE-19 Cells.

7. Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials.

Review 8. Genetics and age-related macular degeneration: a practical review for the clinician.